PTA

GCC Polyethylene Terephthalate Market Analysis Report 2024: PET's Role in Eco-Friendly Packaging Solutions and Versatility in Automotive Applications - Forecast to 2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Packaging, Recycling, Chemicals, Plastics, Automotive Manufacturing, Environment, Manufacturing, MEG, PTA, Urbanization, Growth, Sport, Application, Dow Chemical Company, International, COVID-19, SABIC, PET, Transport, Food, Private sector, RPET, Ethylene glycol, Supply, GCC, Vision 2030, Tourism, Drink, Water, Compound annual growth rate, Polyethylene terephthalate, JBF, Food safety, Food industry, Bottled water

GCC PET market demand is forecasted to grow at a CAGR of 5.30% over the projected period of 2024-2029.

Key Points: 
  • GCC PET market demand is forecasted to grow at a CAGR of 5.30% over the projected period of 2024-2029.
  • GCC PET supply is expected to reach 3.61 million ton by 2029, while GCC PET demand in 2023 stood at 2.20 million ton.
  • Polyethylene Terephthalate (PET), formed by combining purified terephthalic acid (PTA) or dimethyl terephthalate with modified ethylene glycol, exhibits notable impact resistance and ensures food safety.
  • The GCC Polyethylene Terephthalate (PET) market is characterized by a moderately concentrated landscape with several established players vying for market share.

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

BioSkryb Launches New Whole Genome and Transcriptome Core Kits to Accelerate Single-Cell Multiomics

Retrieved on: 
Wednesday, March 13, 2024
Health Technology, Other Health, Technology, Oncology, General Health, Medical Devices, Neurology, Other Technology, Cardiology, Science, Biotechnology, Software, Other Science, Health, Research, PTA, Genome, Gene expression, Transcriptome, DNA, RNA, Figure skating jumps, Marketing, Workflow, Data, Genomics, SVS, WGA, Antibiotics

BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

Key Points: 
  • BioSkryb Genomics , a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.
  • As part of these new kit configurations, total workflow time has been reduced to under eight hours for both products.
  • “These new core kits provide researchers with an optimized and validated workflow that delivers industry-leading single-cell multiomic performance,” said Suresh Pisharody, CEO, BioSkryb.
  • The ResolveOME Whole Genome and Transcriptome Single-Cell Core Kit leverages its PTA-based WGA technology to couple each single cell’s whole genome with its full-length whole transcriptome.

SABER College Opens Enrollment for Comprehensive Physical Therapist Assistant A.S. Degree Program

Retrieved on: 
Wednesday, March 27, 2024
SABER, PTA, Employment, Therapy, Health, Associate, Anatomy, Education, Patient, School, Pell Grant, Interview, Admission, Faculty, Student, Marketing, Mathematics, Curriculum, Workforce, Language, Physical, Nursing

MIAMI, March 27, 2024 /PRNewswire/ -- SABER College is pleased to announce the enrollment opening for its Physical Therapist Assistant (PTA) Associate of Science (A.S.) degree program .

Key Points: 
  • MIAMI, March 27, 2024 /PRNewswire/ -- SABER College is pleased to announce the enrollment opening for its Physical Therapist Assistant (PTA) Associate of Science (A.S.) degree program .
  • Delivered entirely in English, the Physical Therapist Assistant A.S. degree program at SABER College prepares students to enter the dynamic field of healthcare confidently.
  • "Our Physical Therapist Assistant program is a testament to SABER College's unwavering dedication to nurturing individuals' educational aspirations and fostering their evolution into conscientious contributors to society.
  • To be accepted into the Physical Therapist Assistant Program , applicants must meet the following requirements:
    Submission of a SABER college application, including a writing sample
    Attainment of a minimum score of 11.0 in mathematics, language, and reading on the TABE Test (Students with an A.A. degree or higher are exempt)
    For more information about the Physical Therapist Assistant A.S. degree program at SABER College and to begin your journey toward a rewarding healthcare career, visit www.sabercollege.edu or call (305) 443-9170.

OrbusNeich Achieves Record-High Revenue and Net Profit of US$154 Million and US$45.1 Million Respectively, Recommends Final Dividend Payment of HK10 cents per Share

Retrieved on: 
Thursday, March 7, 2024
Stent, Acquisition, MDR, Education, Cardiac catheterization, Sapphire, FDA, Marketing, Quality of life, Medical device regulation, PTCA, Physician, Growth, OrbusNeich, Medicare, PMDA, PTA, Abbott Laboratories, Percutaneous coronary intervention, Patient, Clinical trial, Knowledge, NMPA, Laboratory, Research, PCI

-- Revenue hit record high at US$153.9 million, up 12.5% year-on-year

Key Points: 
  • -- Revenue hit record high at US$153.9 million, up 12.5% year-on-year
    -- Revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year, respectively.
  • In particular, revenue from PCI balloons and PTA balloons grew by 12.1% and 29.0% year-on-year to US$115.4 million and US$14.7 million, respectively.
  • As at December 31, 2023, the Group was in a strong financial position with cash and bank balances amounting to US$255.8 million (2022: US$229.1 million).
  • Having considered future capital requirements, the Board has proposed a final dividend of HK10 cents per share in cash, as a token of appreciation for the continuous support of shareholders.

CARBIOS and Landbell Group join forces to increase circularity of PET waste at first biorecycling plant

Retrieved on: 
Thursday, February 29, 2024
Pros, MEG, Memorandum of understanding, Food packaging, Landbell, Clermont-Ferrand, Indorama Ventures, Ellen, PTA, CO2, Textile, MacArthur Foundation, Recycling, PET, Water, Partnership

The partnership will leverage Landbell Group’s expertise and network in the sourcing of PET packaging and textile waste which will be prepared for biorecycling.

Key Points: 
  • The partnership will leverage Landbell Group’s expertise and network in the sourcing of PET packaging and textile waste which will be prepared for biorecycling.
  • From 2026, Landbell Group will supply CARBIOS with 15 kt/year of PET flakes, ensuring a steady supply chain for sustainable PET production.
  • These flakes will serve as essential feedstock for CARBIOS’ production of food-grade PTA and MEG, further re-polymerized into PET.
  • The innovative depolymerization process developed by CARBIOS facilitates the recycling of PET waste into high-quality recycled PET.

National PTA and Everytown for Gun Safety Announce New Collaboration in the Fight to Protect Kids from Gun Violence

Retrieved on: 
Thursday, March 7, 2024
CAE, Violence, Everytown for Gun Safety, Research, Wound, Gun, Sale, Parent, Curriculum, Life, Conference, Bipartisan Background Checks Act, Safety, School, Fear, Background check, Death, PTA, Policy, Legislation, Congress, Child, Assault weapons ban, Firearm, Nursing

ALEXANDRIA, Va., March 7, 2024 /PRNewswire/ -- With firearm injury now the leading cause of death for children under the age of 19, National PTA and Everytown for Gun Safety have joined forces to help protect children and youth from gun violence and save lives. Through the alliance, National PTA and Everytown will develop tools and resources to empower parent leaders nationwide to influence policy and planning decisions related to gun violence prevention and school safety and preparedness. The announcement of the alliance was made during National PTA's 2024 Legislative Conference in the nation's capital.

Key Points: 
  • Through the alliance, National PTA and Everytown will develop tools and resources to empower parent leaders nationwide to influence policy and planning decisions related to gun violence prevention and school safety and preparedness.
  • As part of the alliance, National PTA and Everytown commissioned a national survey exploring parents' mindsets around school safety and gun violence prevention and policy.
  • Gun safety is important to most parents and over two-thirds would vote for the candidate who supports strengthening gun safety laws.
  • "PTA members across the country have played a critical role in advocating for common sense solutions to gun violence.

PTA Leaders to Convene in the Nation's Capital to Take Action for Kids

Retrieved on: 
Tuesday, March 5, 2024
Unify, Child, National Association, Education, NASSP, Gun violence, Conference, Everytown for Gun Safety, Health, Safety, School, PTA, Congress, Baltimore County Public Schools, PTSA, Communications satellite

ALEXANDRIA, Va., March 5, 2024 /PRNewswire/ --

Key Points: 
  • Hundreds of PTA leaders and education advocates from across the country will come together March 5-7 in Alexandria, Va., for the 2024 National PTA Legislative Conference .
  • They will also hear from speakers and participate in workshops to get an update on issues impacting children, families and schools and grow their advocacy skills.
  • National PTA will recognize Senator Shelley Moore Capito (R-WV) and Representative Jahana Hayes (D-CT-05) during the conference with its 2024 Congressional Voice for Children Award .
  • Additionally, during the conference, National PTA and Everytown for Gun Safety will be announcing a new collaboration.

National PTA Honors Outstanding Advocacy Efforts

Retrieved on: 
Thursday, February 8, 2024
Maker, SNAP, Hoosier, Imagination, Feedback, Restorative justice, Creativity, Textbook, Dollywood Foundation, CAE, Conference, Public, Government, Human, Intellectual disability, PTA, BIPOC, Synthetic, Social media, Equity, Student, Local government, Firearm, Sale, Suicide, Health, Violence, School, Legislation, Child, Education, PTAS, Town, Weapon, Book, Congress, Parent, Nursing

ALEXANDRIA, Va., Feb. 8, 2024 /PRNewswire/ -- National PTA is pleased to announce the recipients of its 2024 Outstanding Advocacy Awards, which honor state, local and individual PTA advocates for taking action to make a difference for the education, health, safety and well-being of every child. The honorees will be recognized during the association's 2024 Legislative Conference, Wednesday, March 6, at The Westin Alexandria Old Town in Alexandria, Va.

Key Points: 
  • In 2023, Thirty-Third District PTA worked on five resolutions—the first resolutions that the PTA had supported in over 10 years.
  • The process allowed Thirty-Third District PTA to not only engage their membership and reinforce the primary role of PTA as an advocacy organization, but it also instilled a sense of pride among their membership for impacting advocacy.
  • "Washington State PTA, Thirty-Third District PTA, Big Creek PTA, Rachel and Maurits exemplify what it means to take action and speak for every child with one voice, which is what our association does best," said Yvonne Johnson, president of National PTA.
  • "I always say to never underestimate the power of a parent's voice, and we are thrilled to recognize the efforts of Washington State PTA, Thirty-Third District PTA, Big Creek PTA, Rachel and Maurits with our 2024 Outstanding Advocacy Awards."

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

Retrieved on: 
Monday, February 5, 2024
Dexmedetomidine, Intelligence, Agitation, Patent, The Orange Book, Schizophrenia, Patient, PTE, Therapy, PTA, IP, Tablet, DSM-IV codes, Bipolar disorder, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 05, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the United States Patent and Trademark Office (“USPTO”) has allowed U.S. Patent Application No. 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form. The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers. The patent, when issued, is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment (“PTA”), patent term extension (“PTE”), and terminal disclaimers.

Key Points: 
  • 17/496,470 with claims pertaining to a method of treating agitation in patients with Alzheimer’s disease using the oromucosal administration of 60 mcg of dexmedetomidine in a water-soluble dosage form.
  • The broad claims encompass film formulations such as BXCL501 (sublingual dexmedetomidine), tablets, or wafers.
  • The patent, when issued, is expected to have an expiration date of Dec. 29, 2037, subject to patent term adjustment (“PTA”), patent term extension (“PTE”), and terminal disclaimers.
  • The Company also announced that it has received an issue notification from the USPTO for U.S. Patent Application No.